Daiichi Sankyo has declared that the first patient has been dosed in a first-in-human Phase 1/2 examination evaluating DS-3939.

VBI Vaccines Inc., a biopharma company specializing in immunology, announced that its cancer immunotherapy vaccine candidate, VBI-1901, has begun a Phase 2b trial in patients with first recurrence glioblastoma.

4D Molecular Therapeutics has begun the Dose Confirmation stage of their Phase 2 SPECTRA trial, enrolling their first patient. The trial evaluates intravitreal 4D-150 for treating diabetic macular edema.

FluoGuide A/S is delighted with the preliminary findings from the FG001 study concerning cancer surgery guidance in head & neck cancer patients.

Tango Therapeutics has received FDA clearance for its IND application for TNG348, a new USP1 inhibitor.

Biotech company Cidara Therapeutics is developing drug-Fc conjugate immunotherapies for serious diseases. Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, has given Cidara a go-ahead for CD388 (JNJ-0953), a universal prevention solution for influenza A and B.

Guangzhou Gloria Biosciences has announced that Zimberelimab injection (YuTuo®, GLS-010), has received marketing approval from the China NMPA.

SpliSense declared the successful completion of a Phase 1 clinical trial for SPL84.

Verismo Therapeutics, a clinical-stage company specializing in CAR-T therapies, has initiated the dosing of the first patient in their STAR-101 clinical trial.

Viking Therapeutics, Inc. has recently commenced a Phase 2 clinical evaluation of VK2735.

Atamyo Therapeutics proclaimed that the FDA has given the green light for its ATA-100 IND application to advance into a Phase 1b/2b clinical study.

VBI Vaccines Inc. publicized that its strategic HBV collaborator, Brii Biosciences announced preliminary group-level unmasked 36-week data from a mid-term examination of a randomly assigned, placebo-controlled, and double-concealed Phase 2 investigation of BRII-179 (VBI-2601).